Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.720
+0.070 (4.24%)
At close: Jun 26, 2026, 4:00 PM EDT
1.745
+0.024 (1.42%)
After-hours: Jun 26, 2026, 7:39 PM EDT
Annovis Bio Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Annovis Bio stock have an average target of 12.5, with a low estimate of 8.00 and a high estimate of 17. The average target predicts an increase of 626.74% from the current stock price of 1.72.
Analyst Consensus: Buy
* Price targets were last updated on May 28, 2026.
Analyst Ratings
The average analyst rating for Annovis Bio stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Reiterates $8 | Buy | Reiterates | $8 | +365.12% | May 28, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $17 | Buy | Reiterates | $17 | +888.37% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.80
from -1.40
EPS Next Year
-1.16
from -1.80
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -1.80 | -1.16 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.